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In a 2-stage study, we iden-
tified an association between
level of radiation-induced
subcutaneous fibrosis and
a nonsynonymous single-
nucleotide polymorphism
(SNP) in TXNRD2
(rs1139793) in a cohort of 92
breast cancer (BC) survivors.
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Open access undePurpose: The aim of the study was to identify noninvasive markers of treatment-induced side
effects. Reactive oxygen species (ROS) are generated after irradiation, and genetic variation
in genes related to ROS metabolism might influence the level of radiation-induced adverse
effects (AEs).
Methods and Materials: 92 breast cancer (BC) survivors previously treated with hypofractio-
nated radiation therapy were assessed for the AEs subcutaneous atrophy and fibrosis, costal frac-
tures, lung fibrosis, pleural thickening, and telangiectasias (median follow-up time 17.1 years).
Single-nucleotide polymorphisms (SNPs) in 203 genes were analyzed for association to AE
grade. SNPs associated with subcutaneous fibrosis were validated in an independent BC survivor
material (nZ283). The influence of the studied genetic variation on messenger ribonucleic acid
(mRNA) expression level of 18 genes previously associated with fibrosis was assessed in fibro-
blast cell lines from BC patients.
Results: Subcutaneous fibrosis and atrophy had the highest correlation (rZ0.76) of all assessed
AEs. The nonsynonymous SNP rs1139793 in TXNRD2 was associated with grade of subcuta-
neous fibrosis, the reference T-allele being more prevalent in the group experiencing severe, Department of Genetics,
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enzyme not previously
implicated in the etiology of
fibrosis. The enzyme is
a central player in ROS
scavenging and is linked to
the mitochondrial respiratory
chain.levels of fibrosis. This was confirmed in another sample cohort of 283 BC survivors, and
rs1139793 was found significantly associated with mRNA expression level of TXNRD2 in blood.
Genetic variation in 24 ROS-related genes, including EGFR, CENPE, APEX1, and GSTP1, was
associated with mRNA expression of 14 genes previously linked to fibrosis (P.005).
Conclusion: Development of subcutaneous fibrosis can be associated with genetic variation in
the mitochondrial enzyme TXNRD2, critically involved in removal of ROS, and maintenance
of the intracellular redox balance.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Earlier detection and more effective multimodal treatments have
improved the prognosis for many cancers. Consequently, the
number of cancer survivors is growing, and the importance of
identifying factors influencing the level of treatment-induced
adverse effects (AEs) increases.
Ionizing radiation (IR) is an important cancer treatment in both
a curative and a palliative setting. Like most cancer treatments,
radiation therapy has the power to heal but is also associated with
long-term complications, both dependent on the properties of
the administered radiation therapy and on the irradiated tissue (1).
In breast cancer (BC) survivors, such long-term sequelae include
lymphedema, impaired shoulder mobility, cardiac dysfunction,
costal fractures, pleural thickening, and subcutaneous fibrosis (2-4).
The effects of IR result from energy deposition in the irradiated
tissues (5). IR may directly damage cellular macromolecules,
including deoxyribonucleic acid (DNA). The indirect IR effects
are mediated through the generation of reactive oxygen species
(ROS) and subsequent by-products, which may ultimately damage
DNA, RNA, and proteins, and deregulate transcription factors and
kinases (5). Several studies have investigated whether genetic
variations in genes involved in radiation-responsive pathways,
such as ROS production, are associated with the development of
adverse effects after radiation therapy, but the results have been
inconsistent. Both chemotherapy and radiation therapy (RT) exert
their antineoplastic effects either directly by attacking cellular
macromolecules, including DNA, or indirectly by generating ROS
and their by-products. Therefore, the genes selected in the present
study are involved in the regulation of redox levels in cells, in cell
signaling affected by the level of ROS or in the repair of DNA
damage caused by ROS, or direct irradiation (6). Specifically,
1030 SNPs in 203 genes were studied for association with the
level of radiation-induced AEs in BC survivors, focusing on the
development of subcutaneous fibrosis. Furthermore, the associa-
tion between these SNPs and the expression level of 18 genes
previously found predictive of fibrosis was studied. The aim was
to identify genetic markers of radiation therapy-induced adverse
effects and to investigate the possible link between the genetic
variation and expression profiles associated with radiosensitivity.Methods and Materials
Ethical considerations
The Regional Committee for Medical and Research Ethics and the
Norwegian Data Inspectorate approved the study. All participants
gave written informed consent.Patient samples and datasets
BC-I
Two hundred sixty-seven women were treated with either a frac-
tionation pattern of 4.3 Gy*10 (nZ155) or 2.5 Gy*20 (nZ88) at the
institute Norwegian Radium Hospital from 1975 to 1986. The
material has previously been thoroughly described (4). The women
were examined for radiation-induced AEs after a median follow-up
time of 15.8 years (range, 10.7-21.8, 4.3-Gy group) and 10.4 (range,
7-22.8, 2.5-Gy group) and had blood samples drawn. Evaluated AEs
included subcutaneous atrophy, telangiectasias, subcutaneous
fibrosis, pleural thickening, development of costal fractures, and
lung fibrosis in the irradiated areas. AEs were scored into groups
according to the late effects in normal tissuesesubjective, objective,
management and analytic (LENT-SOMA) scoring system. The
maximum score of AE was included in the analysis, and women
receivingmultiple treatments to the area investigatedwere excluded.
Ninety-two women from BC-I were included in the initial analyses
(median follow-up time for this subset of samples was 17.1 years),
and the remaining samples were included in the validation step. All
92 women received the hypofractionated treatment of 4.3 Gy*10.
BC-II
Two hundred eighty-three women were treated for BC stage II/III
with postoperative locoregional radiation therapy (2 Gy*25) at the
institute Norwegian Radium Hospital from 1998 to 2002. The
patient cohort has been previously described (7). The level of
subcutaneous fibrosis was assessed 3 to 9 years after BC diag-
nosis, and blood samples were drawn. Whole-genome mRNA
expression profiles from blood were available (8).
Evaluation of subcutaneous fibrosis (BC-I and BC-II) was
performed by an experienced physiotherapist or oncologist and
scored as none (level 1), barely palpable increased density (level
2), increased intensity and firmness (level 3), and very marked
density, retraction, and fixation (level 4), based on the LENT-
SOMA scoring system, and partly using an ad hoc-defined scoring
system developed by the health professionals involved.
Cultured fibroblastswere available from33BCpatients included
in the so-called Aarhus postmastectomy study cohort (9). Normal
fibroblasts were derived from skin biopsy specimens taken from an
unirradiated area of the arm. A score as radiosensitive/radioresistant
based on the development of fibrosis in the irradiated area was
available for 14/33 of the BC patients. Gene expression data from
irradiated fibroblasts were available as previously described (10).
DNA isolation
Leukocyte DNA was isolated from thawed blood containing
ethylenediaminetetraacetate by the use of chloroform/phenol
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Biosystems 340A Nucleic Acid Extractor (BC-I) or the Autopure
LS DNA Purification System (Gentra Systems, Inc, Minneapolis,
MN) (BC-II).
Fibroblast cell lines
DNAwas isolated with Trizol reagent (Invitrogen, Carlsbad, CA).
SNP genotyping
The SNPs for a subset of 92 samples from BC-I (all receiving 4.3
Gy*10) and the fibroblast cell lines were genotyped with the
GenomeLab SNPstream genotyping system. In short, amplified
polymerase chain reaction (PCR) products were used as
a template in a second, modified, single-primer minisequencing
reaction, followed by single-base extension to discriminate the
variant base. The SNP data for BC-I were filtered according to the
following criteria: failure rate >25% (nZ323), monomorphic and
low frequent SNPs with <3 women in 1 genotype group (nZ137),
and SNPs not in Hardy-Weinberg equilibrium (nZ42). Similar
criteria were used to filter SNP data for the fibroblast cell lines,
excluding an additional 16 monomorphic SNPs. The number of
SNPs available for analysis after filtration was 528 and 512 for the
BC-I and fibroblast cell lines, respectively. A more thorough
description of the genotyping can be found in (6).
Seven SNPs were genotyped in BC-II, and the remainder of
BC-I (nZ63 from the 4.3-Gy group and nZ88 from the 2.5-GyFig. 1. (A) Distribution of the adverse effects scored as none (1), litt
lines indicate the groups used in the statistical analysis to identify genet
and above group 2 as indicated in Table 1.) (B) Pairwise correlation rate b
on level of adverse effect using J-Express. (Scale indicates level of advgroup) using the TaqMan 7900HT Fast Real-Time PCR Platform,
according to standard protocol, using 12.2 ng DNA per well. For
rs1139793, the annealing temperature was lowered from 60C to
58C. Genotypes of rs2227306 were only successfully generated
for a subset of the samples, and this SNP was excluded from
further analysis. Information on the custom-made SNP assays is
given in Table E1 (available at www.redjournal.org).Statistical analyses
Data analyses were performed in SPSS (version 18; IBM,
Armonk, NY), J-Express (http://www.molmine.com/), and R
(versions 2.10 and 2.13, http://www.r-project.org).
Correlations between categorical variables were primarily
evaluated by Pearson’s correlation in SPSS; for 2  2 tables, Yates
continuity correction was performed.
Mutual information score analysis and logistic regression
(SNPassoc package in R), was used to assess SNP adverse effect
associations, using all inheritance models (codominant, dominant,
recessive, overdominant, and log-additive). Logistic regression
analyses were used for the multivariate analyses, including
treatment-related factors in the model. No correction for multiple
testing was performed in the discovery analyses in the first 92
samples. In thevalidationanalysesBonferroni correctionswere used.
Linear regression analyses were performed, regressing each
SNP against the mRNA expression level to (1) analyze the effect
of rs1139793 on mRNA level of TXNRD2 both unadjusted andle (2), some (3), and substantial (4) for the BC-I women. (Orange
ic variation associated with level of adverse effect: below group 1
etween the scored adverse effects. (C) Supervised clustering based
erse effect.)
Table 1 Single-nucleotide polymorphisms identified as associated with level of treatment-induced subcutaneous fibrosis for BC-I
Reference sequence
id (rs number) Gene
Genotype distribution* Mutual information score analysis
Allele Nr.tot Group1* Group2* P value
744751 TGFBR2 CC 38 29 9 .0017
CT 41 18 22
TT 12 11 1
731465 TGFBR2 CC 37 28 9 .0018
CG 40 17 22
GG 11 10 1
1139793x TXNRD2 CC 40 29 11 .0215
TC 38 18 20
TT 3 3 0
945222 MGMT GG 46 36 10 .0282
GA 35 17 18
AA 4 3 1
2227306 IL8 CC 19 10 9 .0421
CT 49 38 11
TT 13 6 7
1934951 CYP2C8 GG 60 43 17 .0421
GA 24 11 13
AA 1 1 0
4073 IL8 AA 22 12 10 .0440
AT 49 37 12
TT 18 8 10
Abbreviations: CI Z confidence interval; NA Z not analyzed; NS Z not significant; OR Z odds ratio.
Listed are the results of both univariate and multivariate analyses (corrected for treatment-related factors). The P values are not corrected for multiple
testing.
* Samples divided into 2 groups as indicated in Figure 1, for subcutaneous fibrosis, telangiectasias, and atrophy. Group 1 includes samples from women
experiencing none, little, and some degree of side effects. Group 2 includes those experiencing a substantial level. For costal fractures and pleural
thickening, group 1 includes samples from those experiencing none of these adverse effects versus group 2 consisting of samples from those
experiencing little, some, and substantial effects.
y For the codominant model, the OR and CI are given for heterozygous in the upper line and homozygous in the lower line.
z In the dominant model, the effect of 1 allele masks the effect of the other when both are present. In an overdominant model, the heterozygotes have
a phenotype that is more explicit or better adapted than either of the homozygotes. In a codominant model, both alleles influence the phenotype in
heterozygous individuals.
x Previous id rs2073752.
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model in R); and (2) investigate the influence of ROS-related
SNPs on the mRNA expression level of 18 genes previously
related to fibrosis (eMAP package in R). For the second analysis,
the resulting P values were adjusted for multiple testing by use of
the Benajmini Hochberg FDR correction.
Polyphen (http://genetics.bwh.harvard.edu/pph/), SIFT (http://
sift.jcvi.org/), and Provean (http://provean.jcvi.org/index.php)
score analyses were used to do in silico analysis of the potential
effect of the single base variation T to C in rs1139793 (Ile370Thr)
in TXNRD2 on protein function. PhyloP conservation score was
extracted from UCSC for the position of rs1139793. Two-way
hierarchical clustering of the BC-I survivors based on the level
of AEs was performed in J-Express.
Results
Distribution of AEs
The distribution of AEs among the 4 estimated levels of
damaged(1) none; (2) little; (3) some; and (4) substantialdvaried
considerably (Fig. 1A). Although only a few women hadsubstantial lung fibrosis and costal fractures, more than 30%
experienced substantial levels of subcutaneous fibrosis, subcuta-
neous atrophy, and telangiectasia. The pairwise correlation
between AEs varied from 0.031 (pleural thickening and subcuta-
neous atrophy) to 0.758 (subcutaneous fibrosis and atrophy)
(Fig. 1B). Supervised clustering of all categories of experienced
adverse effects (J-Express) grouped the BC survivors into 2 main
groups, wherein the majority of women experiencing level 3 or 4
for any of the evaluated adverse effects were grouped together in 1
cluster (Fig. 1C).Impact of genetic variation in the ROS pathway on
level of AEs
A total of 528 SNPs genotyped in 92 individuals from the BC-I
cohort, all receiving the hypofractionated treatment, were included
in the analyses. The BC-I survivors were divided in 2 groups to
obtain approximately equal group sizes: either level 1 versus
levels 2, 3, and 4 (for costal fractures and pleural thickening) or
levels 1, 2, and 3 versus level 4 (for subcutaneous fibrosis,
subcutaneous atrophy, and telangiectasias) (Fig. 1A). No analysis
Reference sequence
id (rs number)
Univariated logistic regression Multivariate logistic regression
P value OR (95% CI)y Genetic modelz P value OR (95% CI)y Genetic modelz
744751 .0005 4.89 (1.93-12.41) Overdominant .0002 7.07 (2.27-21.98) Overdominant
731465 .0006 4.92 (1.92-12.6) Overdominant .0004 6.84 (2.2-21.29) Overdominant
1139793x .0120 3.23 (1.27-8.24) Overdominant .0205 2.38 (0.82-6.84)
NA
Codominant
945222 .0049 3.75 (1.46-9.63) Overdominant .0245 3.33 (1.14-9.71) Dominant
2227306 .0104 0.29 (0.11-0.76) Overdominant .0369 0.32 (0.11-0.95) Overdominant
1934951 .0242 3.06 (1.15-8.14) Overdominant .0444 3.24 (1-10.43) Overdominant
4073 .0124 0.32 (0.13-0.8) Overdominant .0134 0.28 (0.1-0.79) Overdominant
Table 1 (continued )
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BC-I women were scored at level 2.
In the univariate analysis, 1 or more SNPs were found to be
associated with the level of all adverse effects by both mutual
information score analysis and logistic regression modeling (not
adjusted for multiple testing): costal fractures, 4 SNPs in GCLC,
MAPK1, KCNMB1, and COX10; pleural thickening, 3 SNPs in
IL1b, PRKD2, and NR1I2; subcutaneous fibrosis, 7 SNPs in
TGFBR2, TXNRD2, MGMT, CYP2C8, and IL8; telangiectasia, 1
SNP in CAT; and subcutaneous atrophy, 3 SNPs in IGF1R and IL8
(Table 1 and Table E2 [available at www.redjournal.org] for
results related to fibrosis and the remaining adverse effects,
respectively). The level of adverse effects was found to be asso-
ciated with 1 or more treatment-related factors such as type of
energy (cobalt or the combination of cobalt with electrons),
surgery (mastectomy/Halsted), treatment period (before/after
1983), and time since treatment (<15 years/15-20 years/>20
years) for all clinical endpoints except pleural thickening (Table
E3A, available at www.redjournal.org). Also, the treatment-
related factors showed variable degrees of correlation (Table
E3B, available at www.redjournal.org). Multivariate analyses,
including the significant treatment-related factors for each adverse
effect (Table E3C, available at www.redjournal.org) showed thatthe identified associations between SNPs and adverse effects were
still significant, with the exception of 2 SNPs associated with the
level of costal fractures (Table 1 and Table E2 [available at www.
redjournal.org]).
Validation of findings related to subcutaneous
fibrosis
Additional samples with data on the development of subcutaneous
fibrosis were available, and the 7 SNPs in TGFBR2, TXNRD2,
MGMT, CYP2C8, and IL8 found associated with subcutaneous
fibrosis in BC-I were analyzed in an independent cohort of 283 BC
survivors (BC-II) and in samples from 62 patients receiving 4.3
Gy*10 and 88 patients receiving 2.5 Gy*20 (remainder of BC-I)
not included in the original genotyping analyses. The SNP in IL8
was only successfully genotyped in subsets of the samples even
after multiple attempts and was excluded from further analysis.
The results confirmed a strong association between rs1139793
(Ile340Thr, T<C) in TXNRD2 and the development of fibrosis in
BC-II. A significantly higher level of the T-allele was found in BC
survivors with more severe grades of fibrosis in both the axilla/
supraclavicular and breast/breast wall region (Fig. 2, Bonferroni
Fig. 2. Genotype distribution of rs1139793 in the TXNRD2 gene across the different levels of subcutaneous damage fibrosis for both
anatomic regions evaluated in the validation set BC-II: (A) axilla/supraclavicular. (B) breast/breast wall.
Edvardsen et al. International Journal of Radiation Oncology  Biology  Physics796adjusted P values .0028 and .014, respectively). Type of chemo-
therapy (FEC/CMF/both/nonstandard treatment) was found
significantly associated with grade of fibrosis (P values .00025 and
.00061 for axilla/supraclavicular region and breast/breast wall,
respectively). Including type of chemotherapy as a covariate, the
association between rs1139793 and grade of fibrosis remained
significant in a logistic regression analysis (overall PZ.007, for
the homozygous TT: P value .002, OR 7.53, 95% CI 2.08-27.2).
Furthermore, the addition of 62 samples from patients receiving
the same treatment of 4.3 Gy*10 to the initial set of 92 patients
samples resulted again in a significant association between
rs1139793 in TXNRD2 and level of treatment-induced subcuta-
neous fibrosis (P value .032) with a higher level of subcutaneous
fibrosis with increasing number of T-alleles. The same trend was
seen for the set of 88 samples collected from patients receiving 2.5
Gy*20.
Association of rs1139793 in TXNRD2 to expression
in blood
The SNP rs1139793 in TXNRD2 was significantly associated with
the TXNRD2 mRNA expression level in blood (in BC-II), with BCFig. 3. Mean mRNA expression level of TXNRD2 in blood
according to genotype group for rs1139793.survivors homozygous for the T-allele showing the highest level of
mRNA expression (PZ.021, linear regression analysis) (Fig. 3).
Previous analysis of the BC-II gene expression data had shown an
association between overall gene expression level and type of
chemotherapy (8). After adjustment for type of chemotherapy in
a linear regression analysis, the association between rs1139793
and mRNA expression level of TXNRD2 was further strengthened
(PZ.0018). The rs1139793 SNP is a nonsynonymous variant
altering the amino acid 370 from isoleucine to threonine. In silico
should be in italics since latin phrase analysis using Polyphen,
Provean, and SIFT all predicted this change to be benign to protein
function (Polyphen score 0.0, effect BENIGN // average Provean
score -1,352, effect NEUTRAL // average SIFT score 0.243, effect
TOLERATED, PhyloP score in mammals for genomic position
chr22:19,868,218 1.43 indicating conservation).
Fibroblast cell lines derived from radiosensitive BC
patients
A score as radioresistant/radiosensitive based on the development
of fibrosis in the region irradiated during breast cancer treatment
was available for 14/33 of the patients from whom we had
fibroblast cell lines (4 radioresistant, 10 radiosensitive). Although
too few to reach statistical significance, the reference T-allele of
rs1139793 in TXNRD2 was only found in the cell lines from the
10 radiosensitive patients (3/10 heterozygote -CT). eQTL analyses
were performed in the fibroblast cell lines to investigate the
influence of ROS-related SNPs on the mRNA expression level of
18 genes previously related to fibrosis by Rodningen et al (10). A
total of 54 associations were identified in trans, representing 24
unique “SNP genes” related to the mRNA level of 14 of the 18
genes (Table 2, unadjusted P value cutoff .005), including
rs1031804 in CENPE associated with mRNA expression level of
CCND2, and rs712831 in EGFR, rs1048945 in APEX1, and
rs1871042 in GSTP1, all associated with the expression level of
ARID5B.
Discussion
Genotype profiling of patients before cancer therapy may help to
identify individuals who will not respond to a given treatment or
who are likely to experience severe adverse effects. To enable
Table 2 eQTL associations identified between genetic variation in 24 reactive oxygen species-related genes and mRNA level of 14
genes linked to risk of fibrosis by Rodningen et al (10), using fibroblast cell lines from breast cancer patients (P value .005)
SNPinfo
Expression gene Raw P valuesrs number MAF Function Gene
rs312185 0.417 Intron AP2S1 MXRA5 .00472
rs1048945 0.061 near_gene_3__missense APEX1 ARID5B .00378
rs210132 0.345 unknown BAK1 MT1H .000715
MT1F .00108
MT1X .00251
rs1031804 0.463 Intron CENPE CCND2 .000336
rs718768 0.267 unknown EGF MT1H .00123
MT1X .0013
ARID5B .0022
MT1F .00288
rs712831 0.212 Intron EGFR ARID5B 8.40E-05
LUM .00037
MT1X .00148
MXRA5 .00215
rs909351 0.034 Intron GSR NF1 .00133
rs1695 0.409 missense GSTP1 NF1 .0045
rs1871042 0.433 Intron ARID5B .00325
rs749174 0.409 Intron NF1 .0045
rs2289807 0.031 Intron MAPK8 NF1 .00244
rs1035413 0.121 Intron MAPK9 ARID5B .00338
rs1042371 0.031 untranslated_3 MYB LUM .00191
NF1 .0027
MT1X .0039
rs967835 0.182 unknown CCND2 .00328
rs2369088 0.371 Intron NDUFA10 CXCL12 .00291
rs2266916 0.370 Intron NOX1 TMEM47 .00159
CXCL12 .00234
MGC33894 .0027
TMEM47 .00333
rs1847137 0.032 intron NOX4 NF1 .0028
LUM .00311
rs317187 0.414 intron C1S .00476
rs1135534 0.034 near_gene_5 PDGFRA MT1X 4.71E-05
LUM .000148
C1S .000188
ARID5B .000569
MT1F .000824
CDON .000947
MT1H .00154
rs854524 0.439 intron PPP1R9A CCND2 .00166
CDON .00287
rs1355984 0.136 intron PRKCA CDON .00322
rs956952 0.125 intron MGC33894 .00287
CDON .00344
rs753279 0.406 intron PRO1580 MT1H .00338
rs5277 0.182 coding_synon PTGS2 ARID5B .00491
rs1921308 0.078 intron TANK NF1 .0037
rs889914 0.078 intron NF1 .0037
rs947712 0.328 intron TGFB2 CDON .000922
rs2842951 0.197 intron TPMT SLC1A3 .000786
rs1366811 0.242 intron LUM .00307
rs1366817 0.333 intron CCND2 .00315
rs1429374 0.288 intron XDH LUM .00144
rs301289 0.179 intron XRCC4 TMEM47 .0037
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influence of the patient’s genetic background on both treatment
response and level of AEs is needed, along with an extended
understanding of the influence of genetic variation on the gene
expression in both tumor cells and normal cells. The present study
used 2 independent BC survivor cohorts and fibroblast cell lines
from a third cohort of BC patients to analyze the influence of
genetic variation in candidate genes from ROS-related pathways
on the level of AEs and on gene expression of genes previously
linked to fibrosis.
The latency for development of 90% of the ultimate severity
and frequency of AEs has previously been estimated to be 3.2
years for fibrosis and 4.7 years for telangiectasias (11), and the
latency time for heart toxicity is reported to be 10 to 15 years (3).
A strength of the present study is the long median follow-up time
of more than 17 years, suggesting that the maximum grade of AEs
had been reached for the BC-I survivors. The tissues typically
receiving higher radiation doses (eg, skin and subcutaneous
tissues) had more severe levels of AEs (telangiectasies, subcuta-
neous atrophy, and subcutaneous fibrosis) than did the tissues
receiving lower radiation doses. These results are in line with
previous findings showing a dose dependency for grade of AEs
after radiation therapy (12). Few studies have analyzed the rela-
tionship between different types of late effects, but a previous
study found no significant correlation between level of telangi-
ectasias and fibrosis (13). By contrast, we see a significant
correlation not only between telangiectasias and fibrosis but also
between several of the other studied endpoints. Also, the clus-
tering analysis revealed 2 distinct clusters with a clear overall
difference in grade of AEs, suggesting that individuals with high
levels of 1 AE may also experience high levels of other AEs.
Subcutaneous fibrosis has been the focal point of genetic
association studies on radiation-induced AEs in BC survivors.
Genetic variation in several genes has been investigated; however,
no consistent associations have been reported. In the current study,
subcutaneous fibrosis was associated with the SNP rs1139793 in
the TXNRD2 gene in the BC-I cohort, and the association was
confirmed in the BC-II cohort, remaining significant after
adjustment for multiple testing. The reference allele (T) was more
prevalent among women experiencing more severe subcutaneous
fibrosis. Furthermore, linear regression showed that rs1139793
was significantly associated with mRNA expression level of
TXNRD2 in blood, and individuals homozygous for the reference
allele had the highest expression levels. Although the expression
level was measured in blood in our study, a previous report
demonstrated high correlations between the expression of
TXNRD2 in blood and breast tissue (14). rs1139793 is located
toward the C-terminal end of the protein, and how genetic varia-
tion in this position influences expression remains to be eluci-
dated, but one may hypothesize that this SNP may be in LD with
other regulatory loci not studied here. TXNRD2 encodes the
selenoprotein thioredoxin reductase 2, a key player in the defense
against oxidative damage, by reducing the oxireductase enzyme
thioredoxin involved in ROS scavenging (15). Knockout studies of
TXNRD2 in mice resulted in embryonic lethality, preferentially
caused by deficient hematopoiesis, impairment in heart develop-
ment, and increased apoptosis in the liver (16). Furthermore,
knockdown of the gene has been shown to significantly increase
the production of hydrogen peroxide, an ROS can be removed,
altogether confirming the essential role of TXNRD2 (15). The
TXNRD2 protein resides in the mitochondria and is reported to
reduce cytochrome c, a complex involved in the respiratory chain(17). To our knowledge, this is the first report of an association
between genetic variation in TXNRD2 and the development of
subcutaneous fibrosis.
eQTL analyses were performed to analyze the influence of
SNPs in the ROS-related genes on the mRNA level of 18 genes
previously linked to fibrosis (10), by use of expression profiles
from irradiated fibroblast cell lines from BC patients. We identi-
fied associations between SNPs in 24 ROS-related genes and
mRNA expression of 14 of the 18 genes. Among the “SNP genes”
showing associations with the mRNA expression were APEX1 and
GSTP1. Several studies have previously investigated genetic
variations in APEX1 and GSTP1 in relation to subcutaneous
fibrosis, all reporting nonsignificant results (4, 18-20).
In conclusion, we identified an association between subcuta-
neous fibrosis and the SNP rs1139793 in TXNRD2 in a cohort of
92 BC survivors, and we confirmed the association in an inde-
pendent cohort of 283 BC survivors. Furthermore, the SNP was
found to be associated with the mRNA expression of TXNRD2 in
blood. eQTL analyses revealed associations between genetic
variation in several ROS-related genes and mRNA expression of
genes previously linked to prediction of risk of subcutaneous
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